Related Experiment Video

Updated: Apr 26, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Preoperative chemotherapy for non-small-cell lung cancer

Gerard G Hanna1, Shankar Siva2, Nikki Plumridge2

  • 1Queen's University of Belfast, Belfast, BT97AE UK.

Lancet (London, England)
|July 22, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

644

Related Experiment Videos

Last Updated: Apr 26, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

644

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

816
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
816
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

919
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
919

Articles linked to this work by shared authors, journal, and citation graph.

'You've Given Me My Voice'-Enhancing Engagement in Exercise Oncology Research: A Patient and Public Involvement Approach to Co‑Designing a Pre‑Radiotherapy Exercise Programme With People Living With Lung Cancer.

Health expectations : an international journal of public participation in health care and health policy·2026

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated Dose.

International journal of radiation oncology, biology, physics·2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Quantifying the AI readiness gap: An international, multidisciplinary assessment of artificial intelligence literacy in the radiation oncology community.

Clinical and translational radiation oncology·2026

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

Lung cancer (Amsterdam, Netherlands)·2026

Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Lancet (London, England)·2026

Generalised eruptive histiocytosis mimicking lymphoma relapse in a patient with previous diffuse large B-cell lymphoma.

Lancet (London, England)·2026

Physiotherapist-led care for musculoskeletal conditions in the emergency department (RESHAP-ED): a randomised controlled trial with economic evaluation.

Lancet (London, England)·2026

Systematic reviews and the needs of the adolescent transgender health care field.

Lancet (London, England)·2026

Pre-eclampsia.

Lancet (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us